Key facts: GSK Q3 sales £8.89bn; £2bn buyback; H1 oncology £1.08bn
GSK reported Q3 2026 sales of £8.89bn (+5% CER), core EPS of 54.6p (+1%), and reaffirmed FY guidance. The company completed a £2bn buyback in Q2, with net debt at £20.74bn. Oncology revenue reached £1.08bn in H1. GSK plans to increase late-stage oncology trials and has tariff relief agreements in place. Key drugs showed positive clinical results.
How this was made
The 30-second read
Why it matters
The earnings release confirms continued revenue growth and a completed buyback, while trial data could drive future pipeline valuation.
Market read
GSK's earnings and trial data provide actionable insight for pharma investors ahead of market open.
What to watch
The reaffirmed guidance suggests limited upside beyond the current quarter, and the buyback may have already been priced in.
Background
GSK's Q3 results and oncology updates were released via multiple sources including Reuters and MarketBeat.
Ticker impact
GSK reported Q3 2026 sales of £8.89bn (+5% CER) and a £2bn buyback, plus positive oncology trial data.
likely modest upside as the market prices in the buyback completion and encouraging trial outcomes
Large‑cap earnings with solid growth and a finished buyback are material; positive oncology data may further boost sentiment.
Market effects
Healthcare sector may see renewed interest in oncology pipelines after GSK's trial results.
UK and European pharma stocks could benefit from the positive earnings and trial news.
Large‑cap pharma earnings influence global risk sentiment and may affect biotech valuations worldwide.
Counterpoint
Investors may view the modest EPS growth and flat vaccine sales as a sign of slowing momentum.
Key entities
- companyGSK
British pharmaceutical giant reporting Q3 2026 results and oncology trial outcomes.
